ClinicalTrials.gg
RecruitingNCT04570163Updated Mar 19, 2026

Berlin Registry of Right Heart Interventions

An observational study in Tricuspid Regurgitation and Pulmonary Regurgitation, sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Charite University, Berlin, Germany · Observational

How we know

From the registry’s dates

  • Started Jun 2020; still recruiting 6 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Tricuspid Valve Insufficiency with a site in Germany — 24 open to participants now, 31 under way, none of them phase 3. Tricuspid Valve Insufficiency · Germany.

Planned enrollment
18th of 26
200 · median 506
Started
2020
with 9 others
Observational
26 of 51
17 open now
Primary completion
2035-12
later than 30 of 30 live
Registered
21st of 51
by date
Lead sponsor
4 of 51
Charite University, Berlin, Germany

Among the 51 studies in Tricuspid Valve Insufficiency with a site in Germany, this one is the 18th largest by planned enrollment of the 26 observational ones that give a count, is one of 10 that started in 2020, is one of 26 observational ones, reaches primary completion later than 30 of the 30 other live ones, and was the 21st registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

24 of the 51 studies in Tricuspid Valve Insufficiency with a site in Germany are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Tricuspid Valve Insufficiency with a site in Germany, or all of them as a file.
02

Study summary

The present study evaluates patients after interventional therapy of valvular diseases of the right heart. Follow-up examinations include medical history taking, laboratory measurements and an echo. The aim is to assess the different interventional therapies and their impact on patient's outcome.

Read the detailed description

The subject of the study is to register interventional therapies of right heart diseases (such as "cardioband" and "edge-to-edge" techniques of the tricuspid valve) performed in Berlin/ Brandenburg (primarily at the Charité, Universitätsmedizin Berlin). Based on the development and the increasing use of interventional therapies in tricuspid and pulmonary valve diseases, the impact on the patients' symptoms and life expectancy after interventions will be investigated. The aim is to identify patient subgroups that benefit the most.

Primary endpoints: Total mortality, cardiovascular mortality, heart failure hospitalization.

Secondary endpoints: NYHA class, NTproBNP, liver and kidney function (laboratory measurements), valve function, cardiac function, and cardiac morphology.

03

Conditions studied

  • Tricuspid Regurgitation
  • Pulmonary Regurgitation
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients after interventional therapy of valvular diseases of the right heart (such as "cardioband" and "edge-to-edge" techniques of the tricuspid valve) performed in Berlin/ Brandenburg (primarily at the Charité, Universitätsmedizin Berlin).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with planned or recent valve interventions of the right heart (tricuspid regurgitation/ stenosis, pulmonary regurgitation/ stenosis)
  • >18 years
  • Written, documented consent

Exclusion criteria

Exclusion Criteria:

  • Patients in care or unable to consent
  • Patients who are unable to comply with follow-up examinations
  • Patients who are detained in an institution
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes

Interventions

  • DeviceInterventional therapy mainly of tricuspid regurgitation (TriClip, Cardioband)

    Catheter-based therapy of valve diseases of the right heart with various devices (e. g. TriClip, Cardioband).

06

What researchers measure

Primary outcomes

  1. Overall mortality

    Number of deceased participants after 2 months after intervention

    Time frame: 2 months after intervention

  2. Cardiovascular mortality

    Number of deceased participants after 2 months after intervention (cardiovascular cause of mortality)

    Time frame: 2 months after intervention

  3. Unscheduled hospitalization for heart failure progression

    Number of participants with unscheduled hospitalization for heart failure progression after 2 months after intervention

    Time frame: 2 months after intervention

Secondary outcomes

  1. NYHA class

    New York Heart Association (NYHA) class (to rate dyspnea in heart failure patients)

    Time frame: 2 months after intervention

  2. NTproBNP

    Laboratory measurement of NTproBNP 2 months after intervention

    Time frame: 2 months after intervention

  3. valve function

    Echocardiographic quantification of valve function (proximal isovelocity surface area \[PISA\] method, effective regurgitant orifice \[ERO\], vena contracta \[VC\]) after 2 months after intervention

    Time frame: 2 months after intervention

  4. liver function

    Laboratory measurement of bilirubin 2 months after intervention

    Time frame: 2 months after intervention

  5. kidney function

    Laboratory measurement of creatinine 2 months after intervention

    Time frame: 2 months after intervention

  6. cardiac function

    Echocardiographic measurement of cardiac function (left ventricular ejection fraction, tricuspid anular plane systolic excursion) after 2 months after intervention

    Time frame: 2 months after intervention

  7. cardiac morphology

    Echocardiographic measurement of cardiac morphology (right ventricular and right atrial diameter) after 2 months after intervention

    Time frame: 2 months after intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — As part of the expected publications, it is planned to provide data of the study participants and more detailed information on inclusion and exclusion criteria (study protocol).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Dec 2035, 186 months after the start.

Of 47 observational studies under Tricuspid Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 106. This study's planned 186 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2020
First posted
Sep 30, 2020
StartActual
Jun 16, 2020
Primary completionEst.
Dec 31, 2035
CompletionEst.
Dec 31, 2035
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04570163
Responsible party
Prof. Dr. Henryk Dreger (Professor, Charite University, Berlin, Germany) — Principal investigator
First posted
Sep 30, 2020
Start date
Jun 16, 2020
Primary completion
Dec 31, 2035 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Mar 19, 2026

Study contacts

Henryk Dreger, Prof. Dr. med.
Contact
henryk.dreger@charite.de
+4930450613496

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion